Terms: = Lymphoma AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1
1371 results:
1. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
2. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.
Brigitha LJ; Mondelaers V; Liu Y; Albertsen BK; Zalewska-Szewczyk B; Rizzari C; Kotecha RS; Pieters R; Huitema ADR; van der Sluis IM
Pharm Res; 2024 Apr; 41(4):711-720. PubMed ID: 38538970
[TBL] [Abstract] [Full Text] [Related]
4. An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI.
Garcia-Ruiz A; Pons-Escoda A; Grussu F; Naval-Baudin P; Monreal-Aguero C; Hermann G; Karunamuni R; Ligero M; Lopez-Rueda A; Oleaga L; Berbís MÁ; Cabrera-Zubizarreta A; Martin-Noguerol T; Luna A; Seibert TM; Majos C; Perez-Lopez R
Cell Rep Med; 2024 Mar; 5(3):101464. PubMed ID: 38471504
[TBL] [Abstract] [Full Text] [Related]
5. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract] [Full Text] [Related]
6. Primary anaplastic large cell lymphoma arising from central nervous system.
Puttirangsan S; Sukswai N; Kongkiatkamon S
J Hematop; 2024 Mar; 17(1):41-44. PubMed ID: 38376722
[TBL] [Abstract] [Full Text] [Related]
7. Paeonol impacts ovarian cancer cell proliferation, migration, invasion and apoptosis via modulating the transforming growth factor beta/smad3 signaling pathway.
Chen XM; Jia CL; Zhu ZY
J Physiol Pharmacol; 2023 Dec; 74(6):. PubMed ID: 38345445
[TBL] [Abstract] [Full Text] [Related]
8. Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Grieve C; Joseph A; Drullinsky P; Zelenetz AD; Hamlin P; Kumar A
Leuk Lymphoma; 2024 Feb; 65(2):235-241. PubMed ID: 38264906
[TBL] [Abstract] [Full Text] [Related]
9. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
Stein EM; Fathi AT; Harb WA; Colak G; Fusco A; Mangan JK
Leuk Lymphoma; 2024 Apr; 65(4):503-510. PubMed ID: 38259250
[TBL] [Abstract] [Full Text] [Related]
10. Busulfan with 400 centigray of total body irradiation and higher dose fludarabine: An alternative regimen for hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia.
Gharial J; Guilcher G; Truong T; Shah R; Desai S; Rojas-Vasquez M; Kangarloo B; Lewis V
Pediatr Blood Cancer; 2024 Apr; 71(4):e30844. PubMed ID: 38217082
[TBL] [Abstract] [Full Text] [Related]
11. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ; Jabbour E; Jain N; Senapati J; Nasr L; Haddad FG; Li Z; Hsiao YC; Yang JJ; Pemmaraju N; Ohanian M; Wierda WG; Montalban-Bravo G; Borthakur G; Han L; Xiao L; Huang X; Abramova R; Zhao M; Garris R; Konopleva M; Ravandi F; Kantarjian H
Blood Adv; 2024 Feb; 8(4):909-915. PubMed ID: 38207208
[TBL] [Abstract] [Full Text] [Related]
12. Maintenance therapy for chronic lymphocytic leukaemia.
Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
[TBL] [Abstract] [Full Text] [Related]
13. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract] [Full Text] [Related]
14. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM; Ando K; Rauzy O; Turgut M; Wang MC; Cairoli R; Hou HA; Kwong YL; Arnan M; Meers S; Pullarkat V; Santini V; Malek K; Kiertsman F; Niolat J; Ramos PM; Menssen HD; Fenaux P; Miyazaki Y; Platzbecker U
Lancet Haematol; 2024 Jan; 11(1):e38-e50. PubMed ID: 38065203
[TBL] [Abstract] [Full Text] [Related]
15. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
[TBL] [Abstract] [Full Text] [Related]
16. Monitoring of blood levels in patients administered CYP3A4 inhibitor during the maintenance phase of venetoclax administration
.
Kubo T; Matsuo S; Sogawa R; Yasu T; Nagaie T; Okamoto S; Kimura S; Shimanoe C
Int J Clin Pharmacol Ther; 2024 Jan; 62(1):56-60. PubMed ID: 37969095
[TBL] [Abstract] [Full Text] [Related]
17. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
[TBL] [Abstract] [Full Text] [Related]
18. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20
Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
[TBL] [Abstract] [Full Text] [Related]
19. Decline of gastric cancer mortality in common variable immunodeficiency in the years 2018-2022.
Milito C; Pulvirenti F; Garzi G; Sculco E; Cinetto F; Firinu D; Lagnese G; Punziano A; Discardi C; Costanzo G; Felice C; Spadaro G; Ferrari S; Quinti I
Front Immunol; 2023; 14():1231242. PubMed ID: 37868983
[TBL] [Abstract] [Full Text] [Related]
20. [Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].
Kong JY; Zong LH; Pu Y; Liu Y; Kong X; Li MY; Zhang J; Song BQ; Xue SL; Tang XW; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):649-653. PubMed ID: 37803838
[No Abstract] [Full Text] [Related]
[Next]
